Side by side
Compare companies
Line up to six companies across valuation, growth, profitability, leverage, ownership and technicals. Best and worst per row are highlighted.
| Metric | MAXHEALTH | MANIPALHOS | FORTIS | ASTERDM | MEDANTA |
|---|---|---|---|---|---|
| Size & Price | |||||
| Market capitalisation | ₹91,573 Cr | ₹91,552 Cr | ₹59,268 Cr | ₹36,728 Cr | ₹36,498 Cr |
| Enterprise value | ₹95,052 Cr | ₹1,02,105 Cr | ₹62,140 Cr | ₹37,429 Cr | ₹37,688 Cr |
| Revenue (TTM) | ₹8,712 Cr | ₹10,336 Cr | ₹9,506 Cr | ₹4,876 Cr | ₹4,683 Cr |
| EBITDA (TTM) | ₹2,318 Cr | ₹2,611 Cr | ₹2,131 Cr | ₹958 Cr | ₹979 Cr |
| PAT (TTM) | ₹1,457 Cr | ₹917 Cr | ₹1,048 Cr | ₹319 Cr | ₹556 Cr |
| Current price | ₹940.95 | ₹696.00 | ₹785.00 | ₹708.90 | ₹1,357.30 |
| 1-day change | +1.2% | -1.74% | +1.95% | +1.69% | -0.56% |
| Avg volume (30d) | — | — | — | — | — |
| 52-week high | — | — | — | — | — |
| 52-week low | — | — | — | — | — |
| Distance from 52w high | — | — | — | — | — |
| Distance from 52w low | — | — | — | — | — |
| Valuation | |||||
| Price to earnings | 62.8× | 99.9× | 56.6× | 115.3× | 65.6× |
| Price to book | 8.5× | 9.7× | 6.0× | 8.0× | 9.2× |
| Price to sales | 10.5× | 8.9× | 6.2× | 7.5× | 7.8× |
| EV / EBITDA | 41.0× | 39.1× | 29.2× | 39.1× | 38.5× |
| Dividend yield | 0.37% | 0% | 0.25% | 0.56% | 0.07% |
| Earnings yield | 1.59% | 1% | 1.77% | 0.87% | 1.52% |
| PEG ratio | 6.73 | 3.39 | 2.7 | — | 3.37 |
| Book value / share | ₹110.4 | ₹71.4 | ₹131.1 | ₹88.3 | ₹147.4 |
| EPS (TTM) | ₹15.0 | ₹7.8 | ₹13.9 | ₹6.2 | ₹20.7 |
| Growth | |||||
| Sales growth (1y) | 19.1% | 25.4% | 17.3% | 12.2% | 19.4% |
| Sales growth (3y CAGR) | 22.4% | 28.8% | 13.2% | -27% | 17.9% |
| Sales growth (5y CAGR) | 27.3% | — | 17.8% | -11.6% | — |
| Profit growth (1y) | 34.1% | -15.3% | 34.6% | -92.8% | 15.6% |
| Profit growth (3y CAGR) | 9.3% | 29.5% | 21% | -3% | 19.5% |
| Profit growth (5y CAGR) | — | — | — | 21.3% | — |
| Qtr sales growth (YoY) | 16.7% | — | 17.5% | 21.6% | 26.5% |
| Qtr profit growth (YoY) | 4.9% | — | 2.3% | -68.7% | -1.1% |
| Profitability | |||||
| Operating margin | 26.8% | 25.3% | 22.8% | 19.4% | 20.8% |
| Net margin | 17.2% | 8.9% | 11.7% | 9.2% | 12.6% |
| Return on equity | 14.3% | 12.8% | 11.1% | 9.7% | 15.1% |
| Return on capital employed | 13.8% | 12.5% | 13% | 11.9% | 16.9% |
| Return on assets | 8.4% | 3.7% | 6.7% | 5.3% | 9.4% |
| ROE (3y avg) | 13.2% | 16.5% | 9.5% | 49.1% | 16.1% |
| ROCE (3y avg) | 13.9% | 15.4% | 11.2% | 6.8% | 18.6% |
| Leverage & Quality | |||||
| Debt to equity | 0.32 | 1.25 | 0.29 | 0.15 | 0.3 |
| Interest coverage | 8.3× | 2.4× | 5.4× | 6.2× | 10.1× |
| Current ratio | 0.89 | 1.22 | 0.86 | 1.99 | 2.67 |
| Working capital days | -110 | 38 | -99 | -112 | -26 |
| Ownership | |||||
| Promoter holding | 23.7% | 72.1% | 31.2% | 40.4% | 33% |
| Promoter pledge | 0% | 0% | 0% | 0% | 0% |
| FII holding | 41.8% | 3.7% | 25.2% | 10.5% | 9.5% |
| DII holding | 30% | 5.2% | 32.2% | 27.7% | 16.9% |
| Public holding | 4.6% | 18.8% | 11.4% | 21.4% | 40.6% |
| Promoter holding change (1y) | -0.03% | — | 0% | 0% | -0.01% |
| Technical | |||||
| 50-day moving average | — | — | — | — | — |
| 200-day moving average | — | — | — | — | — |
| Price vs 50 DMA | — | — | — | — | — |
| Price vs 200 DMA | — | — | — | — | — |
| RSI (14) | — | — | — | — | — |
| Return (1m) | — | — | — | — | — |
| Return (3m) | — | — | — | — | — |
| Return (6m) | — | — | — | — | — |
| Return (1y) | — | — | — | — | — |
| Return (3y CAGR) | — | — | — | — | — |
| Relative strength (1y) | — | — | — | — | — |
| Volatility (1y) | — | — | — | — | — |
| Beta | — | — | — | — | — |
best in row weakest in rowRows without a better/worse direction aren't highlighted.